Wednesday, June 21, 2017 6:43:53 AM
Remember that this trial has the rapid progressors removed, not the pseudoprogressors. We know the effect on overall survival of these patients (when DCVax-L treated )since it’s the 51 patients in the info arm….their mOS came in at 18.3 months with only 1 patient a confirmed pseudoprogressor. So flip I do not buy this argument that the trial is going to do great because they removed the long lived pseudoprogressors.
The other important exclusion criteria is the removal of the biopsy only patients which will make “everybody live longer”. Did anyone stop to think why the placebo arm in the rindopepimut trial came in with a mOS of 21 months? I put it down to 2 factors 1) The exclusion of biopsy only patients (ooops like DCVAx-L) and 2) The selection for EGFRvIII expressing patients that are known to live longer.
If the placebo arm comes in at 21 months mOS for DCVAx-L then it is screwed. However I don’t think it will since there’s no selection for EGFRvIII expression in the DCVax-L trial. Montano et al., Neoplasia, 2011 is actually pretty useful for getting an idea of the life extension due to EGFRvIII expression since it´s kind of internally controlled. Looks like EGFRvIII selection gives about a 4 month survival advantage compared to the general population. Therefore i’d guess that the non-biopsy placebo patient’s in the DCVax-L trial will come in at about 17 months at the high side of SOC which should be OK. It might come in even slightly higher considering the fact the shorter lived rapid progressors have been removed.
From my own analysis with the new data since 5th June this trial is going to have a positive result (at least for OS and assuming no placebo effect) but it’s going to be a lot closer than people think…just to put in my 2 penny worth
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM